AFT Pharmaceuticals: FY23 Result — On Script
We liked what we saw in AFT Pharmaceuticals' (AFT) FY23 result: (1) ANZ revenue (AFT's core defensive growth driver) grew +24% versus FY22, (2)...
345 Views
AFT Pharmaceuticals (AFT): FY23 Result – First Impressions
AFT Pharmaceuticals (AFT) reported an operating FY23 result in-line with guidance and slightly ahead of our expectations with EBIT ex licensing...
337 Views
AFT Pharmaceuticals - Near-term goals in sight with FY23 momentum
AFT Pharmaceuticals reported another strong fiscal year, capping off three consecutive years of double-digit top-line growth. FY23 revenues of...
212 Views
AFT Pharmaceuticals: FY23 Preview — Story Remains Intact
We expect AFT Pharmaceuticals' (AFT) underlying FY23 result to show strong growth, led by its Australia and New Zealand segments, when it reports...
201 Views
AFT Pharmaceuticals - Maxigesic IV closer to FDA approval
AFT Pharmaceuticals has announced that the US FDA has allocated a Prescription Drug User Fee Act (PDUFA) date for Maxigesic IV, an intravenous form...
148 Views